Yajing Chen Sells 1,703 Shares of Zai Lab (NASDAQ:ZLAB) Stock

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CFO Yajing Chen sold 1,703 shares of Zai Lab stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $18.63, for a total value of $31,726.89. Following the completion of the transaction, the chief financial officer directly owned 19,999 shares of the company’s stock, valued at approximately $372,581.37. This represents a 7.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Zai Lab Stock Up 3.8%

NASDAQ:ZLAB traded up $0.69 on Monday, reaching $19.06. 628,981 shares of the company’s stock were exchanged, compared to its average volume of 724,122. The firm has a market capitalization of $2.15 billion, a price-to-earnings ratio of -11.84 and a beta of 0.85. Zai Lab Limited Unsponsored ADR has a 52-week low of $15.96 and a 52-week high of $44.34. The business has a fifty day moving average of $18.65 and a 200-day moving average of $23.06.

Zai Lab (NASDAQ:ZLAB) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.02). The business had revenue of $127.60 million during the quarter, compared to analysts’ expectations of $122.67 million. Zai Lab had a negative net margin of 38.15% and a negative return on equity of 22.81%. As a group, equities analysts anticipate that Zai Lab Limited Unsponsored ADR will post -2.58 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Zai Lab stock. SG Americas Securities LLC boosted its stake in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 6.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 10,396 shares of the company’s stock after acquiring an additional 642 shares during the period. SG Americas Securities LLC’s holdings in Zai Lab were worth $183,000 as of its most recent SEC filing. 41.65% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ZLAB has been the subject of several research reports. Zacks Research downgraded shares of Zai Lab from a “hold” rating to a “strong sell” rating in a research note on Friday, January 23rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zai Lab in a research note on Wednesday, January 21st. Jefferies Financial Group upgraded Zai Lab to a “strong-buy” rating in a report on Monday, January 19th. Cantor Fitzgerald lowered their target price on Zai Lab from $55.00 to $37.00 and set an “overweight” rating for the company in a research note on Friday, February 27th. Finally, UBS Group started coverage on Zai Lab in a research note on Wednesday, January 7th. They set a “buy” rating and a $35.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Zai Lab presently has an average rating of “Moderate Buy” and an average target price of $51.17.

About Zai Lab

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.